NVG-2089

N/A

Report date: 2025/05/21 13:45:55

Base Information

Drug NameNVG-2089
Drug Alias NameNVG-2089
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor II-b modulators
TargetsLow affinity immunoglobulin gamma Fc region receptor II-b
Therapy Area/IndicationsPurpura, Thrombocytopenic, IdiopathicPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNuvig Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNuvig Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic, IdiopathicPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A